The company has a looming opportunity to grab the booming GLP-1 agonist market by the horns.

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for ...

Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk.

The request follows a similar move by Eli Lilly, which has asked for a ban on ... professionals turning to unapproved versions of GLP-1 drugs as an option for weight loss, saying: "This can ...

Pharmaceutical powerhouse Eli Lilly (NYSE: LLY) had a banner year in 2024. The company's sales surged 32% to over $45 billion on massive growth from its GLP-1 agonist products, Mounjaro for treating ...

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...